期刊
DISCOVERIES IN SPINAL CORD INJURY RESEARCH: FROM BENCH TO BEDSIDE
卷 1198, 期 S1, 页码 E22-E34出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2010.05566.x
关键词
spinal cord injury; stroke; animal models; central nervous system; human; myelin protein; Nogo-A; clinical trial; neuroplasticity; axonal regeneration; functional recovery
资金
- Swiss National Science Foundation [31-63633.00, 3100AO-122527/1]
- National Centre for Competence in Research Neural Plasticity & Repair of the Swiss National Science Foundation
- Spinal Cord Consortium of the Christopher
- Dana Reeve Foundation (Springfield, NJ, USA)
- EU
Small lesions of the adult centralnervous system (CNS) often have a good prognosis with extensive functional recovery based in part on spontaneous neuritic sprouting and rearrangements of projections. This is well documented for the cortex, but these changes can also occur in the spinal cord. Nogo-A is a protein present in CNS myelin that inhibits neurite growth. Models of spinal cord injury (SCI) in rats and macaque monkeys demonstrate that treatment with function-blocking antibodies of Nogo-A results in an upregulation of growth-specific proteins, enhanced regenerative and compensatory sprouting of fibers, and the formation of new functional connections in the spinal cord. In animals with unilateral sensorimotor cortex lesions followed by Nogo-A antibody treatment, fibers from the intact corticofugal system crossed the midline, supplying innervation to the denervated brain stem or spinal cord. Behavioral tests showed marked improvements of functional recovery in the Nogo-A antibody treated spinal cord-or brain-injured animals. A Phase I clinical trial applying anti-Nogo-A antibody to subjects with acute SCI has been successfully conducted and a multicentric, multinational Phase II trial is currently in preparation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据